SUDEEPPHRM Share Price Highlights: How has been Its historical performance?

SUDEEPPHRM Share Price Highlights: How has been Its historical performance?

Sudeep Pharma Limited,a Gujarat-based API (active pharmaceutical ingredients) manufacturer recently listed via IPO on November 28, 2025, debuted strongly with shares settling ~30% above the ₹593 issue price at around ₹774, reflecting robust demand for its sterile API niche amid high promoter confidence (76% holding post-IPO). Trading near ₹774 (52-week high ₹795, low ₹725 post-listing), the stock's market cap stands at ₹8,744 Cr with P/E ~63x and P/B 12.9x, signaling premium valuation for a small-cap pharma player with consistent profitability but decelerating sales growth.​

Listing Day and Short-Term Performance

The IPO (November 21-25, 2025; lot size 25 shares at ₹593) listed with explosive volume of 39.75 million shares and VWAP ₹763, delivering 31-33% gains on debut amid bulk deals by entities like Junomoneta Finsol and Irage Broking. Post-listing trends show consolidation: +30.55% day 1, but limited multi-period data as a new entrant; peers like Sun Pharma  trade at lower sector P/E ~40x.​

Pre-IPO Financial Track Record

Prior to listing, Sudeep Pharma demonstrated strong profit compounding (50% CAGR over 5 years) on a base of API production for sterile injectables, with sales up 32% CAGR but slowing to 9-14% recently due to inventory buildup (309 days).​

Fiscal Year	Sales (₹ Cr)	Net Profit (₹ Cr)	EPS (₹)	ROE (%)	OPM (%)
FY20	123	18	128	-	21 ​
FY21	215	33	237	-	20 ​
FY22	343	50	356	-	20 ​
FY24	459	133	945	-	40 ​
FY25	502	139	14	33	38 ​

Q2 FY26 previews show sales ₹125 Cr and PAT ₹31 Cr, with ROCE 35.6% and low debt/equity 0.28.​

Growth Drivers and Valuation Context

Historical strengths include margin expansion (OPM from 20% to 38-40%) via scale in sterile APIs, low capex needs, and working capital efficiency (cash conversion 298 days but improving cash flows ₹23 Cr in FY25). Risks: Promoter stake dip from 89% to 76%, high debtor days (135), and small-cap volatility in pharma; no dividend history yet. Compared to peers (Sun Pharma ROE 15%, Divi's Labs 14.6%), Sudeep's 33% ROE justifies premium but invites scrutiny on sustainability.​

This overview draws from post-IPO data for educational purposes only, not advice—new listings carry high risk; consult SEBI-registered advisors.